The Top 5 Biosimilars Articles for the Week of September 17
The Center for Biosimilars® recaps the top news for the week of September 17, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 17.
Number 5: Chinese researchers are reporting positive preclinical results for a proposed cetuximab biosimilar.
Number 4: Mylan and Fujifilm have revealed that they will launch their adalimumab biosimilar in the European Union on or after October 16.
Number 3: The European Medicines Agency has published new materials intended to educate European patients about biosimilars.
Number 2: The Senate has passed a bill that would eliminate pharmacy gag clauses and require biosimilar and biologics developers to report patent settlements to the Federal Trade Commission.
Number 1: The State of California is suing AbbVie for allegedly using kickbacks and a network of nurses to illegally boost sales of Humira.
Finally, last week, our e-newsletter asked whether you think that interchangeability is the appropriate benchmark for pharmacy-level substitution.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
